<DOC>
	<DOCNO>NCT01195662</DOCNO>
	<brief_summary>The purpose study learn BMS-512148 ( Dapagliflozin ) , 12 week , improve ( decrease ) blood pressure patient type 2 diabetes uncontrolled hypertension Angiotensin-converting enzyme inhibitor ( ACEI ) Angiotensin Receptor Blocker ( ARB ) .The safety treatment also study</brief_summary>
	<brief_title>A Study BMS-512148 ( Dapagliflozin ) Patients With Type 2 Diabetes With Inadequately Controlled Hypertension ACEI ARB Additional Antihypertensive Medication</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Written inform consent Males female , 18 89 year old , type 2 diabetes inadequate glycemic control HbA1c 710.5 % uncontrolled hypertension Systolic Blood Pressure ( SBP ) 140165 Diastolic Blood Pressure ( DBP ) 85105 Subjects must mean 24 hr blood pressure ≥ 130/80 determined Ambulatory Blood Pressure Monitoring ( ABPM ) within 1 week prior Day 1 visit Stable dose oral antidiabetic agent ( OAD ) least 6 week [ 12 wks Thiazolidinedione ( TZD ) ] stable daily dose insulin , monotherapy combination another OAD , 8 week , stable dose ACEI ARB 1 additional antihypertensive medication least 4 week Cpeptide ≥ 0.8 ng/mL Body Mass Index ≤ 45.0 kg/m2 Serum creatinine &lt; 1.50 mg/dL men &lt; 1.40 mg/dL woman Aspartate aminotransferase ( AST ) /or Alanine aminotransferase ( ALT ) &gt; 3.0*upper limit normal ( ULN ) Serum total bilirubin ≥ 1.5*ULN Creatinine kinase &gt; 3*ULN Symptoms severely uncontrolled diabetes History malignant accelerate hypertension Currently unstable serious cardiovascular , renal , hepatic , hematological , oncological , endocrine , psychiatric , rheumatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Angiotensin Receptor Inhibitors</keyword>
	<keyword>Angiotensin-Converting Enzyme Inhibitors</keyword>
	<keyword>Antihypertensive Agents</keyword>
	<keyword>Cardiovascular Agents</keyword>
	<keyword>Pharmacological Actions</keyword>
</DOC>